XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

Summary

A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed bronchial asthma (BA) and the eosinophil blood level 2 times within 1 week interval of ≥ 300 cells/μl. Study design was developed by Chemlmmune Therapeutics LLC, Russia in cooperation with Eurrus Biotech GmbH, Austria.

Timeline

Start

2020-12-16

Primary completion

2021-08-27

Completion

2021-08-27

Drugs

Indications